186 related articles for article (PubMed ID: 25403168)
41. Molecular mechanism of hepatocellular carcinoma-specific antitumor activity of the novel thienopyridine derivative TP58.
Zhou R; Huang WJ; Guo ZY; Li L; Zeng XR; Deng YQ; Hu FY; Tong AP; Yang L; Yang JL
Oncol Rep; 2012 Jul; 28(1):225-31. PubMed ID: 22552608
[TBL] [Abstract][Full Text] [Related]
42. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
43. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
44. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
45. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
46. Vanadium complex: an appropriate candidate for killing hepatocellular carcinoma cancerous cells.
Bakhshi Aliabad H; Khanamani Falahati-Pour S; Ahmadirad H; Mohamadi M; Hajizadeh MR; Mahmoodi M
Biometals; 2018 Dec; 31(6):981-990. PubMed ID: 30255365
[TBL] [Abstract][Full Text] [Related]
47. Structures and cytotoxicity relationship of isoaaptamine and aaptamine derivatives.
Shen YC; Lin TT; Sheu JH; Duh CY
J Nat Prod; 1999 Sep; 62(9):1264-7. PubMed ID: 10514310
[TBL] [Abstract][Full Text] [Related]
48. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J
Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071
[TBL] [Abstract][Full Text] [Related]
49. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
50. Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.
Sun L; Quan H; Xie C; Wang L; Hu Y; Lou L
PLoS One; 2014; 9(3):e90627. PubMed ID: 24598942
[TBL] [Abstract][Full Text] [Related]
51. Noscapine inhibits human hepatocellular carcinoma growth through inducing apoptosis in vitro and in vivo.
Xu G; Niu Z; Dong J; Zhao Y; Zhang Y; Li X
Neoplasma; 2016; 63(5):726-33. PubMed ID: 27468876
[TBL] [Abstract][Full Text] [Related]
52. The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging.
Li H; Du G; Yang L; Pang L; Zhan Y
Anticancer Agents Med Chem; 2020; 20(9):1147-1156. PubMed ID: 32106805
[TBL] [Abstract][Full Text] [Related]
53. Pentoxifylline induces apoptosis of HepG2 cells by reducing reactive oxygen species production and activating the MAPK signaling.
Wang Y; Dong L; Li J; Luo M; Shang B
Life Sci; 2017 Aug; 183():60-68. PubMed ID: 28583366
[TBL] [Abstract][Full Text] [Related]
54. Antineoplastic agents. 499. Synthesis of hystatin 2 and related 1H-benzo[de][1,6]-naphthyridinium salts from aaptamine.
Pettit GR; Hoffmann H; Herald DL; Blumberg PM; Hamel E; Schmidt JM; Chang Y; Pettit RK; Lewin NE; Pearce LV
J Med Chem; 2004 Mar; 47(7):1775-82. PubMed ID: 15027869
[TBL] [Abstract][Full Text] [Related]
55. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
56. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
[TBL] [Abstract][Full Text] [Related]
57. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
58. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
59. Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner.
Aoki S; Kong D; Suna H; Sowa Y; Sakai T; Setiawan A; Kobayashi M
Biochem Biophys Res Commun; 2006 Mar; 342(1):101-6. PubMed ID: 16480688
[TBL] [Abstract][Full Text] [Related]
60. Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB.
Ahmadian E; Eftekhari A; Babaei H; Nayebi AM; Eghbal MA
Anticancer Agents Med Chem; 2017 Nov; 17(11):1570-1577. PubMed ID: 28356024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
